NISHITH.TV
  • Mumbai
  • Silicon Valley
  • Bengaluru
  • Singapore
  • Mumbai BKC
  • New Delhi
  • Munich
  • New York

Locations

  • Mumbai
  • Silicon Valley
  • Bengaluru
  • Singapore
  • Mumbai BKC
  • New Delhi
  • Munich
  • New York
  • Content
  • Home
  • ABOUT US
  • NDA in the Media
  • Areas of Service
  • Research and Articles
  • Opportunities
  • Contact
  • NDACloud
  • Client Access
  • Member Access
  • Events and Calender
  • How we perform
  • Knowledge anywhere, anytime
  • See our recent deals
  • Up to date legal developments
  • Case studies in M&A

Research and Articles

HTMLPDF

  • Research at NDA
  • Research Papers
  • Research Articles
  • NDA Think Tanks
  • NDA Hotline
  • New Ali Gunjan
  • Japan Desk ジャパンデスク

NDA-Hotline


  • Capital Markets Hotline
  • Companies Act Series
  • Climate Change Related Legal Issues
  • Competition Law Hotline
  • Corpsec Hotline
  • Court Corner
  • Cross Examination
  • Deal Destination
  • Debt Funding in India Series
  • Dispute Resolution Hotline
  • Education Sector Hotline
  • FEMA Hotline
  • Financial Service Update
  • Food & Beverages Hotline
  • Funds Hotline
  • Gaming Law Wrap
  • GIFT City Express
  • Green Hotline
  • HR Law Hotline
  • iCe Hotline
  • Insolvency and Bankruptcy Hotline
  • International Trade Hotlines
  • Investment Funds: Monthly Digest
  • IP Hotline
  • IP Lab
  • Legal Update
  • Lit Corner
  • M&A Disputes Series
  • M&A Hotline
  • M&A Interactive
  • Media Hotline
  • New Publication
  • Other Hotline
  • Pharma & Healthcare Update
  • Private Client Wrap
  • Private Debt Hotline
  • Private Equity Corner
  • Real Estate Update
  • Realty Check
  • Regulatory Digest
  • Regulatory Hotline
  • Renewable Corner
  • SEZ Hotline
  • Social Sector Hotline
  • Tax Hotline
  • Technology & Tax Series
  • Technology Law Analysis
  • Telecom Hotline
  • The Startups Series
  • White Collar and Investigations Practice
  • Yes, Governance Matters.
  • Japan Desk ジャパンデスク

Pharma & Healthcare Update

April 1, 2021

Commercialisation of healthcare in India: overview

India is home to some of the world’s largest pharmaceutical companies and makes a significant contribution to the global output of drugs each year. India’s reputation as the pharmacy of the world has only grown in recent years. In the medical device sector as well, India is on its way to making a mark globally. The growth of the Indian pharmaceutical and medical device industry can be attributed in part to the well-established regulatory framework governing drugs and medical devices manufactured and marketed in India. Medicinal products have been regulated in India since the 1940s and the government has been making efforts in recent years to ensure the manner of regulating drugs and medical devices is in line with global standards. This has encouraged many foreign players to consider marketing their products in India as well as sourcing their products from India to meet the demand in other jurisdictions.

In this guide, Dr. Milind Antani, Darren Punnen and Shreya Shenolikar provide a comprehensive overview of the regulatory framework applicable to drugs and medical devices. The guide covers the entire supply chain from approval of drugs and medical devices to their sale to the end consumer. They have also provided information on the manner in which pharmaceutical adjacent products such as alternative medicinal products and nutraceuticals are regulated.

The complete article can be accessed here.

Reproduced from Practical Law with the permission of the publishers. For further information, visit practicallaw.com

 

– Shreya Shenolikar, Darren Punnen & Dr. Milind Antani

You can direct your queries or comments to the authors

Mission and Vision


Distinctly Different

What's New


Rich investors stare at a possible higher tax outgo after Sebi tweaks AIF rules
Quotes: March 31,2023
SEBI approves five proposals on AIF reforms
Investment Funds: Monthly Digest : March 30,2023

Events


Webinars

Sovereign Wealth Fund and Pension Funds investments in India: Unique Considerations and Critical Issues
March 09,2023 - March 09,2023

This event is over. For event material please click here


Seminar

Exploring the Fund Regime and Regulatory Landscape in Abu Dhabi Global Markets
April 12,2023 - April 12,2023

Round Table

Investing In Net Zero
July 22,2022 - July 22,2022

This event is over. For event material please click here

News Roundup


News Articles

Shareholder Activism: An ESG tool or a Founder’s curse?
October 13,2022

Quotes

Rich investors stare at a possible higher tax outgo after Sebi tweaks AIF rules
March 31,2023

Newsletters


Investment Funds: Monthly Digest

SEBI approves five proposals on AIF reforms
March 30,2023

Regulatory Hotline

SEBI Modifies FPI Master Circular: Onboarding Process Streamlined
March 29,2023

Tax Hotline

Amendments to Finance Bill, 2023
March 29,2023

  • Disclaimer
  • Content
  • Feedback
  • Walkthrough
  • Subscribe
Nishith Desai Associates@2016 All rights reserved.